NewAmsterdam Pharma Co (NAMS) Stock Price, Quote, News & History | Benzinga

NewAmsterdam Pharma Co NV (NAMS) Stock Price, Quote, News & History

NAMSNASDAQ

Trade with Public

Trade with Public

$25.85

0.261.02%

At close: Sep 2, 5:00 PM EST

$25.97

0.381.48%

Pre-Market: 5:06 AM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

-

Close

$25.85

Volume / Avg.

28.45K / 1.09M

Day Range

- - -

52 Wk Range

23.05 - 42.21

Market Cap

$3.10B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

40

Short Interest

12.39%

Days to Cover

9.92

Recent NewAmsterdam Pharma Company N.V. News

Monster Beverage, Westrock Coffee, Himax Technologies And Other Big Stocks Moving Higher On Friday

US stocks, including Monster Beverage Corp, rose on Friday. Monster Beverage reported better-than-expected financial results, causing a 12.8% jump in their shares.

Avi Kapoor

Analyst Says NewAmsterdam Stock Has Over 100% Upside, Citing 90% Success Probability For Obicetrapib

NewAmsterdam shared new Phase 3 data showing obicetrapib reduced LDL-C by 33% and impacted Alzheimer's biomarkers ahead of July 2025 presentation.

Vandana Singh

Flywire Posts Downbeat Results, Joins Lemonade, Ginkgo Bioworks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Avi Kapoor

Why ZoomInfo Technologies Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket

Avi Kapoor

Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-143.46M

Investing Cash Flow (TTM)

-34.91M

Financing Cash Flow (TTM)

41.68M

Free Cash Flow (TTM)

-143.72M

Capital Expenditure (TTM)

-260.00K

Net Change in Cash (TTM)

-136.69M

Analyst Trends and Forecast

1

Jun

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.8

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$2.46B

PE Ratio (TTM)

-

PE Ratio (FWD)

135.14

PEG Ratio (TTM)

-

PS Ratio (TTM)

439.33

PB Ratio (TTM)

4.89

Earnings Yield % (TTM)

-8.36%

Earnings Yield % (FWD)

0.74%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$5.28

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$424.15M

Debt to Equity

0.00

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

-

Close

$25.85

Volume / Avg.

28.45K / 1.09M

Day Range

- - -

52 Wk Range

23.05 - 42.21

Market Cap

$3.10B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

40

Short Interest

12.39%

Days to Cover

9.92

About

Sector

Health Care

Industry

Biotechnology

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, i...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy NewAmsterdam Pharma Co (NAMS) stock?

A

You can purchase shares of NewAmsterdam Pharma Co (NASDAQ:NAMS) through any online brokerage.

View our list of the best stock brokerages

Q

Who are NewAmsterdam Pharma Co (NAMS) competitors?

A

Other companies in NewAmsterdam Pharma Co’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for NewAmsterdam Pharma Co (NAMS) stock?

A

NewAmsterdam Pharma Co has a consensus price target of $46.17.

Q

What is the current price for NewAmsterdam Pharma Co (NAMS)?

A

The stock price for NewAmsterdam Pharma Co (NASDAQ: NAMS) is $25.97 last updated September 4, 2026 at 5:06 AM EDT.

Q

Does NewAmsterdam Pharma Co (NAMS) pay a dividend?

A

There are no upcoming dividends for NewAmsterdam Pharma Co.

Q

When is NewAmsterdam Pharma Co (NASDAQ:NAMS) reporting earnings?

A

NewAmsterdam Pharma Co does not have any upcoming earnings scheduled.

Q

Is NewAmsterdam Pharma Co (NAMS) going to split?

A

There is no upcoming split for NewAmsterdam Pharma Co.

Q

What sector and industry does NewAmsterdam Pharma Co (NAMS) operate in?

A

NewAmsterdam Pharma Co is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.